

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
15 August 2024 (15.08.2024)



(10) International Publication Number
WO 2024/168224 A3

(51) International Patent Classification:

A61K 39/155 (2006.01) C07K 14/08 (2006.01)
C07K 14/115 (2006.01) A61K 39/00 (2006.01)
C07K 14/005 (2006.01)

(21) International Application Number:

PCT/US2024/015123

(22) International Filing Date:

09 February 2024 (09.02.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/484,339 10 February 2023 (10.02.2023) US

(71) Applicant: **VERNAGEN, LLC** [US/US]; 1860 Montreal Road, Tucker, Georgia 30084 (US).

(72) Inventors: **KIM, Baek**; c/o Vernagen, LLC, 1860 Montreal Road, Tucker, Georgia 30084 (US). **YOON, Jack**; c/o Vernagen, LLC, 1860 Montreal Road, Tucker, Georgia

30084 (US). **PAK, David**; c/o Vernagen, LLC, 1860 Montreal Road, Tucker, Georgia 30084 (US).



(74) Agent: **PARK, Hyunseok** et al.; Sughrue Mion, PLLC, 2000 Pennsylvania Ave., N.W., Suite 9000, Washington, District of Columbia 20006 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

(54) Title: ENGINEERED NIPAH VIRUS MRNA VACCINE

FIG. 1



(57) Abstract: Provided herein are a Nipah virus vaccine composition including (i) a messenger ribonucleic acid (mRNA) including an open reading frame (ORF) encoding soluble Nipah virus glycoprotein (soluble NiV-G) fused with human collagen type I alpha 1 (COL1A1) signal peptide, (ii) a mRNA including an ORF encoding full-length Nipah virus glycoprotein (full-length NiV-G), (iii) a mRNA including an ORF encoding full-length Nipah virus fusion protein (full-length NiV-F), or (iv) the mRNA including the ORF encoding full-length NiV-G, and the mRNA including the ORF encoding full-length NiV-F, and a method of inducing immune response against Nipah virus by administering an effective amount of the Nipah virus vaccine composition to a subject in need thereof.

[Continued on next page]

WO 2024/168224 A3

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

10 October 2024 (10.10.2024)